Molecular mechanism of imatinib-induced thrombocytopenia in treatment of patients with CML / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 1314-1318, 2011.
Article
in Zh
| WPRIM
| ID: wpr-261877
Responsible library:
WPRO
ABSTRACT
Imatinib mesylate has been commonly used in the treatment of patients with chronic myeloid leukemia (CML). However, a significant number of CML patients treated with imatinib developed thrombocytopenia. Platelet-derived growth factor (PDGF)/platelet-derived growth factor receptor (PDGFR) plays a significant role in the regulation of thrombopoiesis. It is suggested that imatinib may block the PDGF/PDGFR and PI3-K/Akt pathway, then inducing the apoptosis of megakaryocytes and developing thrombocytopenia in these patients. In this review, the potential molecular mechanism of imatinib-induced thrombocytopenia in the treatment of CML patients is discussed, including imatinib and thrombocytopenia, PDGF/PDGFR and thrombopoiesis, potential mechanism of imatinib-induced thrombocytopenia in treatment of patients with CML and so on.
Full text:
1
Database:
WPRIM
Main subject:
Piperazines
/
Pyrimidines
/
Thrombocytopenia
/
Benzamides
/
Platelet-Derived Growth Factor
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Signal Transduction
/
Thrombopoiesis
/
Therapeutic Uses
/
Drug Therapy
Limits:
Humans
Language:
Zh
Journal:
Journal of Experimental Hematology
Year:
2011
Document type:
Article